Sanara Medtech Inc Stock Price, News & Analysis

Sanara MedTech (Nasdaq: SMTI) has launched a pilot program through its subsidiary Tissue Health Plus (THP) for value-based wound care services. The program partners with a wound care provider group operating across six states to deliver at-home chronic wound care.

The THP technology platform will serve as the provider group's Wound Care Operating System, featuring the Co-Pilot software for standardizing patient encounters and treatment interventions. The platform includes two-way EMR integration to streamline administrative processes. The company aims to launch another pilot program with a payer in the second half of 2025.

Sanara MedTech Inc. (NASDAQ: SMTI) reported strong Q1 2025 financial results with net revenue increasing 26% to $23.4 million compared to Q1 2024. The company's soft tissue repair products sales grew 28% to $20.5 million, while bone fusion products increased 18% to $2.9 million. Despite revenue growth, SMTI reported a net loss of $3.5 million, wider than the $1.8 million loss in Q1 2024. The quarter saw significant developments including an exclusive license agreement with Biomimetic Innovations Ltd for OsStic® products, executive team changes, and a loan amendment with CRG allowing additional borrowings. The company ended Q1 with $20.7 million in cash and $42.8 million in debt obligations. Gross margin improved to 92% from 90% year-over-year, though operating expenses increased 30% to $23.7 million.

Sanara MedTech (Nasdaq: SMTI), a medical technology company specializing in surgical, chronic wound and skincare markets, has scheduled its first quarter 2025 financial results announcement for May 14, 2025 before U.S. markets open.

The company will host a conference call and webcast at 8:00 a.m. Eastern Time on the same day to discuss results for the quarter ended March 31, 2025. Investors can join via phone (toll-free: 888-506-0062, international: 973-528-0011, access code: 490762) or webcast. A replay will be available through May 28, 2025 (replay numbers: 877-481-4010, international: 919-882-2331, passcode: 52308).

Sanara MedTech (Nasdaq: SMTI), a medical technology company specializing in surgical, chronic wound and skincare markets, has announced its participation in the Planet MicroCap Showcase: VEGAS 2025. The event will be held at the Paris Hotel & Casino in Las Vegas from April 22-25, 2025.

Management will deliver their presentation on Wednesday, April 23, 2025, at 3:30 p.m. Pacific Time. Investors can access the presentation materials on the company's investor relations website prior to the event. A live audio webcast will be available under the 'Events' section, with a replay option available after the conference.

Sanara MedTech (SMTI) reported strong Q4 2024 financial results with net revenue increasing 49% year-over-year to $26.3 million. Full-year 2024 revenue grew 33% to $86.7 million.

Q4 highlights include:

• Gross profit rose 51% to $24.1 million with 91% margin
• Operating loss of $0.4 million compared to $0.2 million loss in Q4 2023
• Net loss of $1.7 million versus $0.3 million loss in Q4 2023
• Adjusted EBITDA of $0.9 million, up from $0.4 million

The growth was primarily driven by increased sales of soft tissue repair products, particularly CellerateRX Surgical and BIASURGE. The company plans to invest $7.5-10.0 million in Tissue Health Plus segment in H1 2025, with a pilot program launch expected in Q2. As of December 31, 2024, Sanara had $15.9 million cash and $30.5 million in debt obligations.

Sanara MedTech (Nasdaq: SMTI), a medical technology company specializing in surgical, chronic wound and skincare markets, has scheduled its Fourth Quarter and Full Year 2024 financial results announcement for March 25, 2025, before U.S. markets open.

The company will host a conference call and webcast at 8:00 a.m. Eastern Time on the same day to discuss the results for the quarter and year ended December 31, 2024. Investors can join via phone (toll-free: 888-506-0062, international: 973-528-0011, access code: 904042) or watch the live webcast on the company's website. A replay will be available through April 08, 2025.

Sanara MedTech (NASDAQ: SMTI) has announced an exclusive license and distribution agreement with Biomimetic Innovations (BMI), alongside a minority investment of up to €8.0 million for approximately 12.5% equity stake in BMI. The company has made an initial €4.0 million investment, with the remaining €4.0 million contingent on achieving specific milestones.

The agreement grants Sanara exclusive U.S. rights to market, sell, and distribute OsStic®, a synthetic injectable structural bio-adhesive bone void filler, along with related delivery technology. OsStic received FDA Breakthrough Device Designation in December 2023 for periarticular fractures treatment. The technology addresses an estimated 100,000+ annual U.S. procedures.

The five-year agreement includes automatic renewal options. Market introduction is anticipated in Q1 2027, complementing Sanara's existing surgical portfolio.

Sanara MedTech (NASDAQ: SMTI) has announced key changes to its executive leadership team effective January 15, 2025. Elizabeth Taylor has been appointed as Chief Financial Officer, succeeding Michael McNeil, who transitions to the roles of Chief Accounting Officer and Chief Administrative Officer.

Taylor brings over 25 years of financial experience, including previous positions as CFO at Imbed Biosciences, COO of multiple hedge funds, and investment team member at a private equity firm. She most recently served as CFO at Imbed Biosciences from 2023 to 2025, where she managed budgeting, forecasting, and financial analysis. Her background includes founding Burnett Taylor Consulting, serving as COO at PioneerPath Capital and Tala Investments, and working at Thomas H. Lee Partners.

Ron Nixon, Sanara's Executive Chairman and CEO, emphasized that Taylor's combination of industry and Wall Street experience will complement their existing finance and accounting teams as they continue their growth phase in the surgical, chronic wound, and skincare markets.

Sanara MedTech Inc. (SMTI) reported strong preliminary Q4 2024 results with expected net revenue between $25.7-26.2 million, representing a 45-48% year-over-year increase. Full-year 2024 revenue is projected at $86.0-86.5 million, up 32-33% from 2023.

Growth was primarily driven by increased sales of soft tissue repair products, particularly CellerateRX Surgical Activated Collagen and BIASURGE. The company benefited from temporary BIASURGE sales surge ($1.8 million) due to industry-wide IV fluid shortages following Hurricane Helene, expected to normalize in Q1 2025.

As of December 31, 2024, SMTI maintained $15.9 million in cash, $30.5 million in debt obligations, and $24.5 million in available borrowing capacity. The company filed 11 provisional patent applications in 2024 for antimicrobial technologies and hydrolyzed collagen innovations.